VRAYLAR Drug Patent Profile

When do Vraylar patents expire, and when can generic versions of Vraylar launch?

Vraylar is a drug marketed by Abbvie and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-one patent family members in forty-two countries.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the cariprazine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Vraylar

Vraylar was eligible for patent challenges on September 17, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 20, 2029. This may change due to patent challenges or generic licensing.

There has been one patent litigation case involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VRAYLAR

International Patents:	121
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	44
Clinical Trials:	9
Patent Applications:	131
Drug Prices:	Drug price information for VRAYLAR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VRAYLAR
What excipients (inactive ingredients) are in VRAYLAR?	VRAYLAR excipients list
DailyMed Link:	VRAYLAR at DailyMed

See drug prices for VRAYLAR

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VRAYLAR

Constraining patent/regulatory exclusivity:

7,943,621*PED

NDA:

204370

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VRAYLAR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AbbVie	Phase 4
The Medical Research Network	Phase 4
AbbVie	Phase 3

See all VRAYLAR clinical trials

Pharmacology for VRAYLAR

Drug Class

Atypical Antipsychotic

Paragraph IV (Patent) Challenges for VRAYLAR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VRAYLAR	Capsules	cariprazine hydrochloride	1.5 mg, 3 mg, 4.5 mg and 6 mg	204370	3	2019-09-17

US Patents and Regulatory Information for VRAYLAR

VRAYLAR is protected by six US patents and three FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 7,943,621.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-002	Sep 17, 2015		RX	Yes	No
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-004	Sep 17, 2015		RX	Yes	No	RE49110*PED				Y
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-002	Sep 17, 2015		RX	Yes	No	RE49302*PED				Y
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-002	Sep 17, 2015		RX	Yes	No	RE49110*PED				Y
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-005	Dec 18, 2025		RX	Yes	No	RE49110*PED				Y
Abbvie	VRAYLAR	cariprazine hydrochloride	CAPSULE;ORAL	204370-001	Sep 17, 2015		RX	Yes	Yes	7,737,142*PED				Y

International Patents for VRAYLAR

When does loss-of-exclusivity occur for VRAYLAR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Georgia, Republic of

Hong Kong

Hungary

Japan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Nicaragua

Poland

Portugal

Serbia

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VRAYLAR around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2004261490	(thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
Brazil	PI0413283	derivados de (tio)carbamoil-ciclohexano como antagonistas de receptor d3/d2
Canada	2532818	DERIVES DE (THIO) CARBAMOYL-CYCLOHEXANE UTILISES EN TANT QU'ANTAGONISTES DES RECEPTEURS D3/D2 ((THIO) CARBAMOYL-CYCLOHEXANE DERIVATIVES AS D3/D2 RECEPTOR ANTAGONISTS)
China	1829703	(Thio)carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
Cyprus	1113099
Denmark	1663996

Supplementary Protection Certificates for VRAYLAR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1663996	PA2017027	Lithuania		PRODUCT NAME: KARIPRAZINAS, DRUSKOS FORMOS, KONKRECIAI JO HIDROCHLORIDO DRUSKOS FORMOS, T.Y. KARIPRAZINO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/17/1209 20170713
1663996	CR 2017 00042	Denmark		PRODUCT NAME: CARIPRAZINE, OPTIONALLY IN THE FORM OF A SALT, INCLUDING THE CARIPRAZINE HYDROCHLORIDE; REG. NO/DATE: EU/1/17/1209 20170717
1663996	122017000083	Germany		PRODUCT NAME: CARIPRAZIN, GEGEBENENFALLS IN FORM EINES SALZES, EINSCHLIESSLICH CARIPRAZINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/17/1209 20170713
1663996	300913	Netherlands		PRODUCT NAME: CARIPRAZINE, OPTIONEEL IN DE VORM VAN EEN ZOUT, WAARONDER CARIPRAZINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/17/1209 20170717
1663996	47/2017	Austria		PRODUCT NAME: CARIPRAZIN, GEGEBENENFALLS IN FORM EINES SALZES, EINSCHLIESSLICH CARIPRAZIN HYDROCHLORID; REGISTRATION NO/DATE: EU/1/17/1209 (MITTEILUNG) 20170717
1663996	LUC00039	Luxembourg		PRODUCT NAME: CARIPRAZINE, OPTIONALLY IN THE FORM OF A SALT, INCLUDING THE CARIPRAZINE HYDROCHLORIDE; AUTHORISATION NUMBER AND DATE: EU/1/17/1209 20170717

VRAYLAR (cariprazine) market dynamics and financial trajectory: exclusivity, competitive threats, and earnings exposure

Last updated: June 3, 2026

Vraylar (cariprazine) has remained a high-margin, specialty-priced atypical antipsychotic franchise in schizophrenia and bipolar disorder, with growth driven by (1) neurologic and functional positioning versus older agents, (2) branded penetration through formulary access, and (3) label expansion that broadened addressable patient populations. The financial trajectory is now dominated by patent and exclusivity timelines in the US and key ex-US markets, plus the pace and strategy of biosimilar or generic disruption for small-molecule rivals and next-generation antipsychotics.

What drives VRAYLAR market dynamics in schizophrenia and bipolar disorder?

Vraylar’s commercial engine is a multi-indication platform with consistent clinician use in schizophrenia and bipolar I disorder, bolstered by a partial dopamine agonist profile and practical titration experience relative to older SGAs.

Which clinical areas contribute most to VRAYLAR demand?

• Schizophrenia (adult): core volume driver.
• Bipolar mania (adults; bipolar I disorder): recurring demand tied to relapse prevention patterns.
• Bipolar depression (adult; bipolar I disorder): label-driven incremental adoption.
• Adjunctive and real-world persistence: refill behavior supports repeat purchasing once patients are stabilized.

How do payer and formulary dynamics affect VRAYLAR pricing power?

Key dynamics that determine whether Vraylar holds or loses share after competitor entries:

• Prior authorization (PA) and step edits: shape early formulary access and reduce switching friction unless clinical documentation is strong.
• Formulary tier placement: Vraylar’s specialty positioning depends on whether it is placed as a preferred SGA or requires higher patient cost-sharing.
• Copay programs and contracting: influence net price and churn between SGAs within a formulary class.
• PBM utilization management: drives share migration to lower net-price alternatives when competitive pressure rises.

When does VRAYLAR lose exclusivity, and what are the generic or biosimilar risks?

Vraylar is a small-molecule product, so the risk channel is generic oral cariprazine (ANDA) rather than biosimilars. Loss of exclusivity is therefore a question of patent term + regulatory exclusivities + Orange Book coverage, not biologics pathways.

US exclusivity and Orange Book coverage: what determines generic entry timing?

Generic entry in the US hinges on:

• Patent expiration dates for drug substance and formulated products
• Method-of-use patents tied to schizophrenia/bipolar dosing and therapeutic regimens
• Patent-by-patent strength after Paragraph IV filings
• Regulatory exclusivities only where they apply (small-molecule typically relies more on patents than exclusivity)

What patent estate features matter most for VRAYLAR’s launch blockers?

In practice, the most consequential blockers for a generic cariprazine entry are:

• Drug substance patents that prevent an ANDA from relying on the same manufactured intermediates or crystalline forms without infringement risk
• Formulation or dosage unit patents that target specific oral formulations, release profiles, or stability approaches
• Method-of-use patents that align claims with labeled populations and treatment regimens

How strong is the patent protection for VRAYLAR versus generic challengers?

Vraylar’s strength profile is determined by how many independently valuable Orange Book-listed patents map to:

1. active ingredient manufacture,
2. formulation/dosage delivery, and
3. clinically relevant use.

Patent estate structure that typically delays generic “at-risk” launches

A robust estate delays entry through:

• Stacked expiration dates across families (substance, formulation, use)
• Narrow but high-injunction leverage (where a generic design-around still reads on a claim)
• Multiple asserted patents in litigation that stretch time to resolution

What patent litigation and Paragraph IV challenges affect VRAYLAR timelines?

The practical launch timetable for generics is driven by:

• Whether Paragraph IV challenges were filed against Orange Book-listed patents
• District court case timelines (including motions, claim construction, and trial schedules)
• Settlement agreements that trigger delayed launch dates
• Appeals that extend uncertainty and delay actual FDA approvals

Settlement-driven delays: what to watch

When litigation resolves via settlement, generic launch dates often reflect:

• A negotiated design-around carve-out (if a non-infringing version is required)
• Staggered entry across strengths or indications
• Conditions tied to inventory, labeling, or market launch choreography

What does VRAYLAR’s competitive landscape look like in atypical antipsychotics?

Vraylar competes in a crowded SGA arena where net price, access rules, and prescriber switching costs matter.

Which competitor classes pressure VRAYLAR?

• Other oral SGAs for schizophrenia and bipolar indications
• Long-acting injectables (LAIs) that reduce adherence-driven relapse costs
• Newer agents with differentiated safety/tolerability narratives that can win formulary preference

How does Vraylar’s differentiation translate to share retention?

Commercial retention tends to correlate with:

• Stable patient response and clinician trust after initiation
• Reduced early switching when patients tolerate the titration pattern
• Prescriber preference where efficacy and safety profiles align with real-world needs

How does VRAYLAR’s financial trajectory track to market share and net pricing?

Vraylar’s earnings profile is sensitive to:

• Net price changes (rebates, discounts, PBM contracting, patient assistance)
• Volume growth (new starts and persistence)
• Mix shift across indications and doses
• Legal and regulatory costs linked to patent defense and litigation

What are the key financial drivers to model forward?

High-signal drivers for a quarterly model:

• US prescription and TRx growth rates (before and after label events or competitor incursions)
• Net product revenue trends versus gross-to-net assumptions
• Gross margin impacts from contracting changes
• Operating expense impacts from litigation and ongoing market access activities

How do acquisition and manufacturing scale factors influence VRAYLAR margins?

For branded small molecules, gross margin is mostly a function of:

• API and formulation manufacturing efficiency
• Inventory management
• Supply chain disruptions that force temporary pricing adjustments or expedite shipments
• Ongoing cost of goods and quality system compliance

What generic entry scenarios could be most damaging to VRAYLAR revenue?

Generic threats are not uniform; they vary by:

• Strength-level exclusivity (if some strengths are blocked longer)
• Formulation patent coverage (if only certain tablet strengths are covered)
• Labeling carve-outs that allow some generic launches earlier but with constrained promotional claims

Scenario tree for revenue exposure (US)

• Base case: no generic launch until later in the exclusivity curve; Vraylar sustains growth or flattens with competitive churn.
• Downside case: earlier at-risk entry or a broader ANDA approval triggers share loss; revenue compresses as the net price declines faster than volume.
• Severe case: aggressive price competition plus formulary switches cause material TRx erosion, requiring promotional reinforcement and contracting concessions.

How do international markets affect VRAYLAR’s global financial trajectory?

Global exposure depends on:

• Local patent term lengths and enforcement outcomes
• Regulatory filing timelines for competitors in each geography
• Pricing regulation and reimbursement structures that may cap branded discounts
• Local generics/parallel imports that can increase net price pressure

Common international risk patterns

• Earlier generic launches in jurisdictions with shorter patent effective periods
• Regulatory approval speed for locally filed ANDAs
• Tendering dynamics that force major payor re-contracting and rapid switching

What is the Orange Book status of VRAYLAR?

Vraylar’s Orange Book status is defined by the set of listed patents for each drug product and strength, including:

• Drug substance and drug product patents
• Method-of-use patents
• Associated expiration dates
• Listed NDA and patent-categorization codes that reflect coverage type

This Orange Book mapping determines:

• Whether a generic can file an ANDA with “paragraph IV” against specific listed patents
• The eligibility for 30-month stay and subsequent launch timing
• The scope of injunction risk and settlement structure

How does VRAYLAR compare with competing antipsychotics on market durability?

Vraylar’s durability is assessed on:

• Index-to-category share among oral SGAs
• Persistence and discontinuation behavior relative to competing agents
• Adherence capture versus LAIs, where patient-level switching can be adherence-driven

Commercial durability signals to track

• US net growth deceleration versus competitor share expansion
• Changes in formulary placement for SGAs within PBM portfolios
• Growth in bipolar depression share versus schizophrenia share
• Stronger retention in stable cohorts versus incident-only growth

Key takeaways

• Vraylar’s market dynamics are driven by multi-indication penetration, formulary access constraints, and net pricing mechanics that shape share retention in a crowded SGA field.
• Financial trajectory is most sensitive to US patent and Orange Book coverage, plus the timing and outcome of Paragraph IV challenges and settlement-based delayed launches.
• Competitive impact is conditional on generic entry scenarios that vary by strength, formulation coverage, and label carve-outs, with the largest downside coming from rapid PBM-driven switching and accelerated net price compression.
• International revenues introduce additional timing risk because patent term and regulatory approval clocks differ materially across jurisdictions.

FAQs

1. What types of patents typically delay generic cariprazine ANDA launches for VRAYLAR?
2. How do PBM formulary decisions change net pricing for VRAYLAR during competitive entry?
3. What are the most revenue-sensitive strengths or dose forms for VRAYLAR if generic entry occurs?
4. How does Vraylar’s bipolar depression label adoption affect quarterly TRx and mix?
5. What litigation events most reliably predict delayed generic launch dates for a branded SGA like VRAYLAR?

References

1. FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration.
2. FDA. “Patent and Exclusivity Information.” U.S. Food and Drug Administration.
3. FDA. “ANDA (Abbreviated New Drug Application).” U.S. Food and Drug Administration.
4. FDA. “NDA Approval and Labeling Information.” U.S. Food and Drug Administration.

DrugChatter Q&A for VRAYLAR

When will vraylar be available in generic?
Vraylar competitive landscape pharmaceutical market analysis?
When will vraylar become generic?
How long has vraylar been on the market?
Vraylar regulatory exclusivity?